31 Results for "

CDC25B

" in MedChemExpress (MCE) Product Catalog:
Products (31)

31 Results for "CDC25B" in MCE Product Catalog:

9
9 Publications Verification
Cat. No.: HY-108543
CAS No.: 93718-83-3
Purity:  ≥99.0%
Target:  

Phosphatase Apoptosis

Research Areas:  

Cancer

NSC 95397 is a potent, selective Cdc25 dual specificity phosphatase inhibitor (Ki=32 nM (Cdc25A), 96 nM (Cdc25B), 40 nM (Cdc25C); IC50=22.3 nM (human Cdc25A), 56.9 nM (human Cdc25C), 125 nM (Cdc25B)) . NSC 95397 inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) and suppresses proliferation and induces apoptosis in colon cancer cells through MKP-1 and ERK1/2 pathway .
6
6 Cited Publications
Cat. No.: HY-100034
CAS No.: 383907-43-5
Purity:  99.29%
Synonyms: DA-3003-1
Research Areas:  

Cancer

NSC 663284 (DA-3003-1) is a potent, cell-permeable, and irreversible Cdc25 dual specificity phosphatase inhibitor, has an IC50 for Cdc25B2 of 0.21 μM. NSC 663284 exhibits mixed competitive kinetics against Cdc25A, Cdc25B(2), and Cdc25C with Ki values of 29, 95, and 89 nM, respectively . NSC 663284 inhibits NSD2 (IC50 of 170 nM) through a direct interaction with the catalytic SET domain (Kd of 370 nM) .
3
3 Cited Publications
Cat. No.: HY-135457
CAS No.: 1954650-11-3
Purity:  ≥98.0%
Target:  

Phosphatase STAT Ras

Research Areas:  

Cancer

JMS-053 is an efficient and reversible PTP4A3 inhibitor, with an IC50 value of 18 nM. JMS-053 demonstrates broad PTP4A inhibitory activity with IC50s of 50 nM and 53 nM for PTP4A1 and PTP4A2, respectively. JMS-053 exhibits IC50 values of 92.6 nM and 207.6 nM for CDC25B and DUSP3, respectively. JMS-053 can effectively inhibit the activity of PTP4A3, inhibit tumor cell proliferation and migration through multiple mechanisms such as interfering with RhoA and STAT3/p38 signaling pathway. JMS-053 can be used for the study of cancers such as ovarian cancer, breast cancer and colon cancer .
1
1 Cited Publications
Cat. No.: HY-126246
CAS No.: 2374831-10-2
Purity:  98.09%
Target:  

Phosphatase

Research Areas:  

Cancer

CDC25B-IN-1 (compound 4a) is a potent inhibitor of cell division cycle 25B (CDC25B) phosphatase, with a Ki of 8.5 μM. CDC25B-IN-1 potently inhibits cell proliferation and colony formation, causes an increase of the G2/M phase .
1
1 Cited Publications
Cat. No.: HY-112776A
CAS No.: 1049740-43-3
Purity:  99.36%
Target:  

Phosphatase

Research Areas:  

Cancer

BN82002 hydrochloride is a potent, selective and irreversible inhibitor of CDC25 phosphatase family. BN82002 hydrochloride inhibits CDC25A, CDC25B2, CDC25B3, CDC25C CDC25A, and 25C-cat with IC50 values of 2.4, 3.9, 6.3, 5.4, and 4.6 µM, respectively. BN82002 hydrochloride displays ~20-fold greater selectivity over CD45 tyrosine phosphatase .
Cat. No.: HY-151986
CAS No.: 2864407-22-5
Purity:  99.54%
Target:  

FOXM1 DNA/RNA Synthesis

Research Areas:  

Cancer

FOXM1-IN-1 is a potent FOXM1 inhibitor with an IC50 value of 2.65 µM. FOXM1-IN-1 shows antiproliferative activity. FOXM1-IN-1 decreases the the expression of FOXM1, PLK1, CDC25B protein .
Cat. No.: HY-132578
CAS No.: 2832887-40-6
Target:  

Phosphatase

Research Areas:  

Cancer

M5N36 is a potent and selective Cdc25C inhibitor with IC50 values of 0.15, 0.19, 0.06 µM for Cdc25A, Cdc25B, Cdc25C, respectively. M5N36 shows anti-proliferative activity and increases the expression of p-CDK1 and p-CDK2 .
Cat. No.: HY-112776
CAS No.: 396073-89-5
Target:  

Phosphatase

Research Areas:  

Cancer

BN82002 is a potent, selective and irreversible inhibitor of CDC25 phosphatase family. BN82002 inhibits CDC25A, CDC25B2, CDC25B3, CDC25C CDC25A, and 25C-cat with IC50 values of 2.4, 3.9, 6.3, 5.4, and 4.6 µM, respectively. BN82002 displays ~20-fold greater selectivity over CD45 tyrosine phosphatase .
Cat. No.: HY-P11228
Research Areas:  

Cancer

FPP29 is a potent peptide-based FOXM1 PROTAC degrader. FPP29 induces ubiquitination and degradation of FOXM1. FPP29 inhibits FOXM1 via the ubiquitin-proteasome degradation pathway. FPP29 induces Apoptosis. FPP29 suppresses tumor growth in hepatocellular carcinoma xenograft models. FPP29 can be used in the research of hepatocellular carcinoma (cell-penetrating peptide: (HY-P0133); VHL ligase ligand: (HY-P11493); linker: (HY-W013664); FOXM1 ligand: (HY-P11494)) .
Cat. No.: HY-137175A
CAS No.: 134271-74-2
Purity:  97.02%
Target:  

Phosphatase

Research Areas:  

Cancer

CDC25B-IN-2 is a potent cdc25B inhibitor .
Cat. No.: HY-W024644
CAS No.: 59147-84-1
Target:  

Phosphatase

Research Areas:  

Cancer

Hydroxyethylthio Vitamin K3 is a Cdc25 phosphatase inhibitor, with IC50 values of 4.56 μM and 23.63 μM for Cdc25A and Cdc25B, respectively. Hydroxyethylthio Vitamin K3 can be used in tumor research .
Cat. No.: HY-121065
CAS No.: 477603-18-2
Purity:  ≥95.0%
Synonyms: IRC-083065
Target:  

Phosphatase

Research Areas:  

Cancer

BN-82685 is a a quinone-based CDC25 inhibitor with IC50 of 201 nM, 117 nM, 109 nM, 160 nM, 249 nM, for CDC25C, CDC25C-cat, CDC25A, CDC25B2, CDC25B3, respectively. BN-82685 plays an important role in cancer research .
Cat. No.: HY-RS02292
Research Areas:  

Others

CDC25B Human Pre-designed siRNA Set A contains three designed siRNAs for CDC25B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-128769
CAS No.: 2376577-06-7
Purity:  98.19%
Target:  

CDK

Research Areas:  

Cancer

M2N12 is a potent and highly selective cell division cycle 25C protein phosphatase (Cdc25C) inhibitor with an IC50 value of 0.09  μM. M2N12 also has promising activity against Cdc25A and Cdc25B with IC50 values of  0.53  μM and 1.39 μM, respectively. M2N12 has anti-tumor activity and can be used for cancer research .
Cat. No.: HY-137990
CAS No.: 3774-64-9
Purity:  97.75%
Questin is an anthraquinone compound and antibacterial agent. Questin can be isolated from marine-derived fungi and plants. Questin inhibits Cdc25B phosphatase. Questin exhibits antibacterial activity against V. harveyi, V. anguillarum, V. cholerae, and V. parahemolyticus with MIC values of 31.25 µg/mL, 62.5 µg/mL, 62.5 µg/mL, and 125 µg/mL. Questin displays antiprotozoal activity against the animal protozoan pathogen Tritrichomonas foetus, with a MIC of 12.5 µg/mL. Questin has anticancer activity against lung and colon cancer .
Cat. No.: HY-172807
CAS No.: 2133007-20-0
Research Areas:  

Cancer

p38α-IN-9 (Compound 2015) is a p38α inhibitor and blocks p38α’s enzymatic activity with an IC50 lower than 20 nM. p38α-IN-9 inhibits MK2 T334 phosphorylation. p38α-IN-9 activates Cdc25b and Cdc25c and simultaneously inactivates Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy and DNA damage. p38α-IN-9 Inhibits colorectal cancer (CRC) metastasis .
Cat. No.: HY-RS19767
Research Areas:  

Others

Cdc25b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdc25b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-RS26264
Research Areas:  

Others

Cdc25b Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdc25b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-N12177
CAS No.: 1647101-05-0
Cryptosporioptide A (Compound 3) is a pigment protein tyrosine phosphatase inhibitor derived from the insect-parasitic fungus Cordyceps gracilioides. Cryptosporioptide A inhibits PTP1B, SHP2, CDC25B, LAR and SHP1 enzymes with IC50 of 7.3, 5.7, 7.6, >50, 4.9 μg/mL, respectively .
Cat. No.: HY-W102931
CAS No.: 6541-19-1
Target:  

Phosphatase

Research Areas:  

Cancer

6,7-Dichloroquinoline-5,8-dione (compound DA3002) is a potent CDC25B2 inhibitor with an IC50 value of 4.6 µM. 6,7-Dichloroquinoline-5,8-dione has the potential for the research of cancer .